Treating complicated carbapenem-resistant enterobacteriaceae infections with ceftazidime/avibactam: a retrospective study with molecular strain characterisation

International Journal of Antimicrobial Agents

Volumn 49, Issue 6, 2017, Pages 770-773

  Krapp, Fiorella ^a   Grant, Jennifer L ^a   Sutton, Sarah H ^a   Ozer, Egon A ^a   Barr, Viktorija O ^b,c  

^a NORTHWESTERN UNIVERSITY   (United States)

^b NORTHWESTERN MEMORIAL HOSPITAL   (United States)

^c ROSALIND FRANKLIN UNIVERSITY OF MEDICINE AND SCIENCE   (United States)

Author keywords

Carbapenem resistant Enterobacteriaceae; Ceftazidime avibactam; Klebsiella pneumoniae; Multidrug resistance; Lactamase inhibitor

Indexed keywords

AVIBACTAM PLUS CEFTAZIDIME; METALLO BETA LACTAMASE; POLYMYXIN B; TIGECYCLINE; ANTIINFECTIVE AGENT; AVIBACTAM, CEFTAZIDIME DRUG COMBINATION; AZABICYCLO DERIVATIVE; BACTERIAL PROTEIN; BETA LACTAMASE INHIBITOR; CEFTAZIDIME;

ANTIBIOTIC RESISTANCE; ARTICLE; BACTERIAL GENOME; BACTERIAL STRAIN; CARBAPENEM RESISTANT ENTEROBACTERIACEAE; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG EFFICACY; DRUG WITHDRAWAL; ENTEROBACTERIACEAE INFECTION; HUMAN; KLEBSIELLA PNEUMONIAE; KLEBSIELLA PNEUMONIAE INFECTION; MINIMUM INHIBITORY CONCENTRATION; PRIORITY JOURNAL; RELAPSE; RETROSPECTIVE STUDY; TREATMENT DURATION; TREATMENT OUTCOME; ADULT; AGED; CARBAPENEM-RESISTANT ENTEROBACTERIACEAE; CLASSIFICATION; DRUG EFFECTS; FEMALE; GENETICS; GENOTYPE; ISOLATION AND PURIFICATION; MALE; MICROBIAL SENSITIVITY TEST; MICROBIOLOGY; MIDDLE AGED; TERTIARY CARE CENTER; UNITED STATES;

ADULT; AGED; ANTI-BACTERIAL AGENTS; AZABICYCLO COMPOUNDS; BACTERIAL PROTEINS; BETA-LACTAMASE INHIBITORS; CARBAPENEM-RESISTANT ENTEROBACTERIACEAE; CEFTAZIDIME; DRUG RESISTANCE, BACTERIAL; ENTEROBACTERIACEAE INFECTIONS; FEMALE; GENOTYPE; HUMANS; MALE; MICROBIAL SENSITIVITY TESTS; MIDDLE AGED; RETROSPECTIVE STUDIES; TERTIARY CARE CENTERS; TREATMENT OUTCOME; UNITED STATES;

EID: 85017532374     PISSN: 09248579     EISSN: 18727913     Source Type: Journal    
DOI: 10.1016/j.ijantimicag.2017.01.018     Document Type: Article

References (17)

1. Munoz-Price, L.S., Poirel, L., Bonomo, R.A., Schwaber, M.J., Daikos, G.L., Cormican, M., et al. Clinical epidemiology of the global expansion of Klebsiella pneumoniae carbapenemases. Lancet Infect Dis 13 (2013), 785–796.
2. Tzouvelekis, L.S., Markogiannakis, A., Piperaki, E., Souli, M., Daikos, G.L., Treating infections caused by carbapenemase-producing Enterobacteriaceae. Clin Microbiol Infect 20 (2014), 862–872.
3. Daikos, G.L., Tsaousi, S., Tzouvelekis, L.S., Anyfantis, I., Psichogiou, M., Argyropoulou, A., et al. Carbapenemase-producing Klebsiella pneumoniae bloodstream infections: lowering mortality by antibiotic combination schemes and the role of carbapenems. Antimicrob Agents Chemother 58 (2014), 2322–2328.
4. Zhanel, G.G., Lawson, C.D., Adam, H., Schweizer, F., Zelenitsky, S., Lagacé-Wiens, P.R., et al. Ceftazidime–avibactam: a novel cephalosporin/β-lactamase inhibitor combination. Drugs 73 (2013), 159–177.
5. Levasseur, P., Girard, A.M., Miossec, C., Pace, J., Coleman, K., In vitro antibacterial activity of the ceftazidime–avibactam combination against Enterobacteriaceae, including strains with well-characterized β-lactamases. Antimicrob Agents Chemother 59 (2015), 1931–1934.
6. Levasseur, P., Girard, A.M., Lavallade, L., Miossec, C., Pace, J., Coleman, K., Efficacy of a ceftazidime–avibactam combination in a murine model of septicemia caused by Enterobacteriaceae species producing AmpC or extended-spectrum β-lactamases. Antimicrob Agents Chemother 58 (2014), 6490–6495.
7. Lucasti, C., Popescu, I., Ramesh, M.K., Lipka, J., Sable, C., Comparative study of the efficacy and safety of ceftazidime/avibactam plus metronidazole versus meropenem in the treatment of complicated intra-abdominal infections in hospitalized adults: results of a randomized, double-blind, phase II trial. J Antimicrob Chemother 68 (2013), 1183–1192.
8. Vazquez, J.A., González Patzán, L.D., Stricklin, D., Duttaroy, D.D., Kreidly, Z., Lipka, J., et al. Efficacy and safety of ceftazidime–avibactam versus imipenem–cilastatin in the treatment of complicated urinary tract infections, including acute pyelonephritis, in hospitalized adults: results of a prospective, investigator-blinded, randomized study. Curr Med Res Opin 28 (2012), 1921–1931.
9. Gardner, S.N., Hall, B.G., When whole-genome alignments just won't work: kSNP v2 software for alignment-free SNP discovery and phylogenetics of hundreds of microbial genomes. PLoS ONE, 8, 2013, e81760.
10. Shields, R.K., Potoski, B.A., Haidar, G., Hao, B., Doi, Y., Chen, L., et al. Clinical outcomes, drug toxicity, and emergence of ceftazidime–avibactam resistance among patients treated for carbapenem-resistant Enterobacteriaceae infections. Clin Infect Dis 63 (2016), 1615–1618.
11. Castanheira, M., Farrell, S.E., Krause, K.M., Jones, R.N., Sader, H.S., Contemporary diversity of β-lactamases among Enterobacteriaceae in the nine U.S. census regions and ceftazidime–avibactam activity tested against isolates producing the most prevalent β-lactamase groups. Antimicrob Agents Chemother 58 (2014), 833–838.
12. Sader, H.S., Castanheira, M., Flamm, R.K., Mendes, R.E., Farrell, D.J., Jones, R.N., Ceftazidime/avibactam tested against Gram-negative bacteria from intensive care unit (ICU) and non-ICU patients, including those with ventilator-associated pneumonia. Int J Antimicrob Agents 46 (2015), 53–59.
13. Liu, Y.M., Li, B.B., Zhang, Y.Y., Zhang, W., Shen, H., Li, H., et al. Clinical and molecular characteristics of emerging hypervirulent Klebsiella pneumoniae bloodstream infections in mainland China. Antimicrob Agents Chemother 58 (2014), 5379–5385.
14. Neuner, E.A., Gallagher, J.C., Pharmacodynamic and pharmacokinetic considerations in the treatment of critically ill patients infected with carbapenem-resistant Enterobacteriaceae. Virulence 9 (2016), 1–13.
15. Veillette, J.J., Truong, J., Forland, S.C., Pharmacokinetics of ceftazidime–avibactam in two patients with KPC-producing Klebsiella pneumoniae bacteremia and renal impairment. Pharmacotherapy 36 (2016), e172–7.
16. McKinnon, P.S., Paladino, J.A., Schentag, J.J., Evaluation of area under the inhibitory curve (AUIC) and time above the minimum inhibitory concentration (T>MIC) as predictors of outcome for cefepime and ceftazidime in serious bacterial infections. Int J Antimicrob Agents 31 (2008), 345–351.
17. Roberts, J.A., Paul, S.K., Akova, M., Bassetti, M., De Waele, J.J., Dimopoulos, G., et al. DALI: defining antibiotic levels in intensive care unit patients: are current β-lactam antibiotic doses sufficient for critically ill patients?. Clin Infect Dis 58 (2014), 1072–1083.